Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
about
The pan-HDAC inhibitor panobinostat acts as a sensitizer for erlotinib activity in EGFR-mutated and -wildtype non-small cell lung cancer cells.Pharmacokinetic parameters of gefitinib predict efficacy and toxicity in patients with advanced non-small cell lung cancer harboring EGFR mutations.How 'Optimal' are Optimal Sampling Times for Tyrosine Kinase Inhibitors in Cancer? Practical Considerations.Development of a skin rash within the first week and the therapeutic effect in afatinib monotherapy for EGFR-mutant non-small cell lung cancer (NSCLC): Okayama Lung Cancer Study Group experience.
P2860
Phase II trial of erlotinib in patients with advanced non‑small‑cell lung cancer harboring epidermal growth factor receptor mutations: additive analysis of pharmacokinetics.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh
2013年學術文章
@zh-hant
name
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@en
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@nl
type
label
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@en
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@nl
prefLabel
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@en
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@nl
P2093
P2860
P1476
Phase II trial of erlotinib in ...... analysis of pharmacokinetics.
@en
P2093
Kazuhiro Tsukamoto
Kazumi Sano
Kohei Motoshima
Kosuke Mizoguchi
Minoru Fukuda
Seiji Nagashima
Shigeru Kohno
Shinnosuke Takemoto
Takaya Ikeda
Tetsuya Iida
P2860
P2888
P304
P356
10.1007/S00280-013-2307-6
P577
2013-12-01T00:00:00Z